摘要
目的探讨生长抑素联合注射用埃索美拉唑钠治疗上消化道出血患者的临床效果。方法选取2018年1月至2020年4月盘锦市人民医院收治的68例上消化道出血患者作为研究对象,按随机数字表法分为对照组与观察组,各34例。两组接受基础治疗,对照组采用注射用埃索美拉唑钠治疗,观察组采用生长抑素+注射用埃索美拉唑钠治疗,比较两组的治疗效果。结果观察组治疗有效率91.18%高于对照组70.59%,差异有统计学意义(P<0.05)。观察组48 h再出血率2.94%低于对照组20.59%,差异有统计学意义(P<0.05)。两组治疗前超敏C反应蛋白(hs-CRP)、皮质醇(COR)、肿瘤坏死因子-α(TNF-α)水平比较,差异无统计学意义(P>0.05);治疗后,观察组hs-CRP(104.32±15.66)mg/L、COR(250.37±20.16)μg/L、TNF-α(10.05±2.11)g/L低于对照组hs-CRP(165.93±18.71)mg/L、COR(310.82±24.81)μg/L、TNF-α(19.97±3.67)g/L,差异有统计学意义(P<0.05)。结论针对各种原发病导致的上消化道出血,在积极开展常规对症治疗的基础上,采用生长抑素联合注射用埃索美拉唑钠治疗,可获得更加满意的疗效。
Objective To analyze the clinical efficacy of somatostatin + Nexium in the clinical treatment of patients with upper gastrointestinal bleeding, hoping to provide a reference for the clinical treatment of such patients. Methods From January 2018 to April 2020, a total of 68 patients with upper gastrointestinal hemorrhage admitted to People’s Hospital of Panjin City were selected as the research objects and were divided into a control group and an observation group according to a random number table, with 34 cases in each group. The control group was treated with Nexium treatment, and the observation group was treated with growth.Stastatin + Nexium treatment. Compare the treatment effects of the 2 groups. Results The total effective rate of treatment in the observation group was 91.18% higher than that in the control group 70.59%, and the data was statistically different(P<0.05). The 48 h rebleeding rate of the observation group was 2.94% lower than that of the control group, 20.59%, and the data was statistically different(P<0.05). Before the 2 groups received treatment, the levels of hs-CRP, COR, and TNF-α were not statistically different(P>0.05). After different treatment plans, the observation group hs-CRP(104.32±15.66) mg/L, COR(250.37±20.16) mg/L and TNF-α(10.05±2.11) mg/mL are lower than the control group hs-CRP(165.93±18.71) mg/L, COR(310.82±24.81) μg/L, TNF-α(19.97±3.67) Mg/mL, the data was statistically different(P<0.05). Conclusion For the upper gastrointestinal bleeding caused by various primary diseases, on the basis of actively carrying out conventional symptomatic treatment, the treatment of somatostatin combined with esomeprazole sodium for injection can obtain a more satisfactory effect and is worthy of clinical promotion.
作者
闫伟
张丹
YAN Wei;ZHANG Dan(Department of Emergency,People's Hospital of Panjin City,Panjin 124221,China)
出处
《中国药物经济学》
2022年第2期91-94,共4页
China Journal of Pharmaceutical Economics
